Q3 2022 Results slide image

Q3 2022 Results

Company overview Financial performance Financial review Appendix 2022 priorities Innovation: Pipeline overview Appendix Innovation: Clinical trials References Abbreviations 30 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation